| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| ARK Investment Management · Cathie Wood | $3.5M | 0.02% | 277.09K | −5.2% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a DRTS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 20, 2026 | Levy RaphiChief Financial Officer | Conversion of Exercise of derivative security at price 2.98 per share. | 2.9K | $8.56K |
| Aug 20, 2026 | Levy RaphiChief Financial Officer | Sale at price 15.00 per share. | 2.9K | $43.07K |
| Aug 10, 2026 | Levy RaphiChief Financial Officer | Conversion of Exercise of derivative security at price 2.98 per share. | 17.7K | $52.84K |
| Aug 10, 2026 | Levy RaphiChief Financial Officer | Sale at price 14.00 per share. | 17.7K | $248.28K |
| Jul 5, 2026 | Levy RaphiChief Financial Officer | Conversion of Exercise of derivative security at price 2.98 per share. | 2.3K | $6.76K |
| Jul 5, 2026 | Levy RaphiChief Financial Officer | Sale at price 14.00 per share. | 2.3K | $31.78K |
| Jul 1, 2026 | Levy RaphiChief Financial Officer | Conversion of Exercise of derivative security at price 2.98 per share. | 17.9K | $53.26K |
| Jul 1, 2026 | Levy RaphiChief Financial Officer | Sale at price 13.00 per share. | 17.9K | $232.40K |
| Jun 30, 2026 | Levy RaphiChief Financial Officer | Conversion of Exercise of derivative security at price 2.98 per share. | 2.1K | $6.34K |
| Jun 30, 2026 | Levy RaphiChief Financial Officer | Sale at price 13.02 per share. | 2.1K | $27.69K |
| Jun 29, 2026 | Levy RaphiChief Financial Officer | Sale at price 12.00 per share. | 20K | $240.04K |
| Jun 24, 2026 | Levy RaphiChief Financial Officer | Sale at price 11.00 per share. | 20K | $220.00K |
| Jun 22, 2026 | Levy RaphiChief Financial Officer | Sale at price 9.47 - 10.00 per share. | 17.5K | $167.05K |
| Jun 2, 2026 | Levy RaphiChief Financial Officer | Sale at price 10.76 - 10.90 per share. | 32.5K | $352.12K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 40.2 | 11.8 | -8.9 | 18.0 | 29.9 | 16.2 | -6.3 | 19.7 | 5.7 | -6.8 | +180.6% | ||
| 2025 | 19.4 | -18.4 | -16.9 | 2.0 | 16.6 | 4.5 | -1.6 | 11.4 | 31.9 | -7.6 | -4.7 | 24.7 | +59.7% |
| 2024 | 10.3 | -9.6 | -1.7 | -15.3 | 0.4 | 0.8 | -13.8 | 12.4 | -2.9 | -1.7 | 19.7 | 10.7 | +3.0% |
| 2023 | 25.2 | -20.6 | -9.2 | 6.6 | 29.7 | 10.1 | -9.4 | -17.2 | 15.5 | -5.0 | -8.9 | -8.2 | −5.3% |
| 2022 | 1.6 | 9.3 | 8.2 | -27.8 | -9.2 | 16.4 | 22.1 | -30.5 | -23.6 | -28.1 | -5.0 | -20.3 | −67.6% |
| 2021 | 0.7 | -0.9 | 0.1 | 1.9 | 0.2 | 0.1 | 0.7 | 0.0 | -1.1 | +1.7% |
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
Buy / hold / sell counts